Figure 4. Charaterization of phenotypic tumor-associated MDSCs following DFMO treatment.

(A) Percent splenic Gr1⁺CD11b⁺ MDSCs were determined by flow cytometry from B16F10-bearing mice. Percent CD11b⁺Ly6G⁺Ly6C^low (granulocytic) and CD11b⁺Ly6G⁻Ly6C^high (monocytic) MDSCs were indicated within plots (5 mice per group). (B) Percent Gr1⁺CD11b⁺ MDSCs, CD11b⁺Ly6G⁺Ly6C^low (granulocytic) and CD11b⁺Ly6G⁻Ly6C^high (monocytic) MDSCs in spleen and tumor tissues from B16F10-bearing mice were summarized (5 mice per group). (C) Measurement of ODC activity in Gr1⁺CD11b⁺ cells from naïve and B16F10 tumor-bearing (TB) mice treated by DFMO or dH₂O (5 mice per group). (D) Expression levels of CD39, CD73, CD115, MHC-II, B7H1, DCFDA (ROS indicator) and arginase-I among both tumor-infiltrating CD11b⁺Ly6G⁺Ly6C^low (granulocytic) and CD11b⁺Ly6G⁻Ly6C^high (monocytic) MDSCs were determined by flow cytometry. Cells were collected from B16F10-bearing DFMO treated or control mice 14 days after tumor inoculation (5 mice per group). Data (mean ± SEM) are representative of 2 independent experiments. *, p< 0.05.